Single nucleotide polymorphisms that modulate microRNA regulation of gene expression in tumors

Gary Wilk¹ and Rosemary Braun^{2,3,*}

¹Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL 60208, USA

²Biostatistics Division, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

³Department of Engineering Sciences and Applied Mathematics, Northwestern University, Evanston, IL 60208, USA

*To whom correspondence should be addressed. Tel: +312-503-3644; Email: rbraun@northwestern.edu

March 21, 2018

Abstract

Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with trait diversity and disease susceptibility, yet the functional properties of many genetic variants and their molecular interactions remains unclear. It has been hypothesized that SNPs in microRNA binding sites may disrupt gene regulation by microRNAs (miRNAs), short non-coding RNAs that bind to mRNA and downregulate the target gene. While a number of studies have been conducted to predict the location of SNPs in miRNA binding sites, to date there has been no comprehensive analysis of how SNP variants may impact miRNA regulation of genes.

Here we investigate the functional properties of genetic variants and their effects on miRNA regulation of gene expression in cancer. Our analysis is motivated by the hypothesis that distinct alleles may cause differential binding (from miRNAs to mRNAs or from transcription factors to DNA) and change the expression of genes. We previously identified pathways—systems of genes conferring specific cell functions—that are dysregulated by miRNAs in cancer, by comparing miRNA–pathway associations between healthy and tumor tissue. We draw on these results as a starting point to assess whether SNPs in genes on dysregulated pathways are responsible for miRNA dysregulation of individual genes in tumors. Using an integrative analysis that incorporates miRNA expression, mRNA expression, and SNP genotype data, we identify SNPs that appear to influence the association between miRNAs and genes, which we term "regulatory QTLs (regQTLs)": loci whose alleles impact the regulation of genes by miRNAs. We describe the method, apply it to analyze four cancer types (breast, liver, lung, prostate) using data from The Cancer Genome Atlas (TCGA), and provide a tool to explore the findings.

1 Introduction

MicroRNAs (miRNAs) are small noncoding RNA molecules that modulate gene expression post-transcriptionally by means of complementary base pairing with mRNA transcripts. Through recognition of short target motifs (6-8 bases long) on the target mRNA, miRNAs bind and down-regulate the expression of the targetted gene. Regions flanking the "seed region" of the miRNA typically also bind the mRNA, creating a stronger annealing between the two RNA molecules. This results in the transcript being prevented from being translated into protein or degraded in the cell [1]. Because these molecular interactions are executed through base pairing, they can be influenced by genomic variation; changes in genome sequence may influence binding energy and the strength of annealing, or may even abrogate miRNA target sites entirely [2].

Polymorphisms constitute approximately 1% of the human genome and contribute to phenotypic diversity and susceptibility to disease. As such, large-scale resources to annotate known single nucleotide polymorphisms (SNPs) have been constructed, including dbSNP [3] and the International Hapmap Project [4], to describe all known patterns of genetic variation. Polymorphisms in miRNA and target site sequences have been implicated in aberrant miRNA-mRNA interactions and have been associated with multiple cancers [5–7], suggesting a link bewteen genetic variation, miRNA regulation, and disease. Typically, discoveries of prognostic SNPs come from genome-wide association studies (GWAS), which statistically link variants with phenotypic traits. Recent GWAS studies have demonstrated that polymorphisms in miRNA binding sites increase the risk of breast [8,9], bladder [10], and colon [11,12] cancers, among others. In addition, several studies [2,5] have suggested that polymorphisms within miRNA regulatory networks affect clinical outcomes and treatment responses.

In recent years, SNPs and their functional effects on miRNA regulation of genes have gained significant interest due to observed genetic variation within miRNA networks, and several databases and computational tools have been developed dedicated toward the study of polymorphic miRNA binding sites. These resources include PolymiRTS [13] (a database which links polymorphisms with miRNAs and target sites, in addition to diseases and biological pathways), Patrocles [14] (polymorphisms which are predicted to perturb miRNA-gene regulation, including eQTLs and Copy Number Variations), and dbSMR [15] (SNPs around miRNA target sites, genome-wide). These resources have improved the search for polymorphic binding sites and their potential functional effects in the cell. Analogous resources exist to study variation within transcription factor (TF) and TF binding sites [16].

GWAS arrays are not comprehensive, however, and often under-sample genomic variants within known miRNA binding regions in the genome [17]. Additionally, while SNP variants may be predicted to affect miRNA-gene regulation based on their genomic position, the magnitude of the effect is often unclear. Hence, GWAS data alone is often insufficient to fully explore the relationship between genetic variation and miRNA regulation. Recently, researchers have combined GWAS data with separate miRNA expression data in head and neck squamous cell (HNSCC) carcinoma to assess variants genome-wide affecting miRNA pathways in cancer [18]. There, the authors first conducted a GWAS to identify HSNCC-associated SNP loci, cross-referenced them against putative miRNA:mRNA binding sites, and confirmed that those miRNAs exhibited differential expression in the TCGA HSNCC data. To date, however, no attempts have been made to directly integrate SNP, miRNA, and gene expression data from the same samples to identify SNPs that disrupt miRNA-gene associations, and the functional effects of many polymorphisms and their molecular interactions remain unknown.

To consider the functional effects of SNPs in miRNA networks, several criteria are required as outlined in [19]. These criteria include independent association with the phenotype of interest, gene expression within the tissue, allelic changes which result in differential binding between miRNA and target gene(s), and resultant differential target gene expression. Concrete guidelines were suggested for future investigations to combine genetic and functional evidence for polymorphisms in miRNA target sites and human disease [7]. Follow-up functional experiments were suggested, in order to strengthen evidence of differential regulation. However, functional binding experiments are experimentally costly at scale, and are typically applied to specific systems of interest. As an alternative, several *in silico* tools have been developed to predict SNP effects on miRNA-gene interactions [20,21]. However, these tools often fail to predict interactions that have been been observed in experiment [22].

To date, the functional effects of polymorphisms are typically explored by integrating GWAS and gene expression data find expression Quantitative Trait Loci (eQTLs): SNP variants that result in altered gene expression. Many eQTLs have been identified, including several associated with cancer. Recent integrative analyses using data from The Cancer Genome Atlas (TCGA) identified eQTLs in Breast Cancer [23] and Glioblastoma Multiforme [24,25]. In fact, combinations of GWAS data with eQTL studies have found alleles that affect gene expression and complex traits genome-wide [26]. However, these analyses do not necessarily reveal the functional effects of polymorphisms on molecular-molecular interactions, particularly with respect to differential binding, as in miRNA-gene or TF-gene interactions.

Data from the TCGA project provides an ideal opportunity to investigate the function of genetic vairants by integrating SNP, gene expression, and miRNA expression from the same set of samples. Here, we propose a method to integrate these data to reveal genetic variants that show evidence of impacting miRNA-gene regulatory relationships. Motivated by the observation that integrative omics analyses provide more insight than single-platform approaches [27,28], we perform an integrative omics analysis that searches for polymorphisms that modulate co-expression between miRNAs and their putative gene targets, which we term "regulatory QTLs (regQTLs)": loci whose alleles impact the regulation of genes by miRNAs. Using mRNA expression, miRNA expression, and genotype data taken from tumor tissues, our method applies a regression model to assess whether disparate alleles present at a genomic variant modulate the miRNA-gene co-regulatory relationship. By comparing miRNA expression and gene expression across genotypes, we can identify regQTLs, or polymorphic sites which may alter molecular interactions and may be implicated in tumorigenesis. Importantly, by using miRNA and gene expression data, we avoid the inaccuracies associated with miRNA binding prediction algorithms, and are able to directly estimate the magnitude of the impact that the SNP has on the regulatory relationship.

Below, we present the method and apply it to TCGA data from four separate cancer types (breast, lung, liver, prostate). We report findings of gene variants that modulate miRNA regulation of gene expression in each of the cancer types studied. Interestingly, some of the flagged miRNAs and genes have been previously implicated in tumorigenic processes in the literature, and SNPs demonstrate functional changes to gene regulation. These results may have implications for future research in genomic regulation in tumors.

2 Methods

We seek to identify regQTLs, genomic variants that influence miRNA regulation of gene expression, by integrating genomic and expression data from TCGA data. Specifically, we test whether different alleles at a SNP locus within a given gene alters how a miRNA modulates the expression of that gene across TCGA tumor samples. regQTLs may then provide context to gene regulation in cancer, due to genetic diversity or genetic alterations.

Previously [29], we had identified sets of genes, or pathways, whose overall activity appeared to be dysregulated by miRNAs in tumors in comparison to healthy tissue in four separate cancer types (breast, lung, liver, prostate). Our method first obtained an expression-based summary of pathway activity using Isomap [30], and then searched for differential miRNA correlations with the pathway summary across phenotypes, to find miRNA-pathway relationships at the systems level that were disrupted in cancer. Using data from The Cancer Genome Atlas (TCGA), we tested ~10⁵ unique miRNA-pathway relationships, many of which were significantly dyregulated.

Here we focus on those dysregulated miRNA-pathway pairs, and explore whether SNPs on the pathways are responsible for miRNA dysregulation of individual genes within that pathway. In other words, for each

miRNA-pathway pair, we explore the co-expression patterns between the miRNA and the genes on the pathway, modulated by each of the polymorphisms located on the gene. By restricting our focus to genes in dysregulated miRNA-pathway pairs, we can ensure that the polymorphisms under consideration reside within perturbed systems in cancer. In addition, this restriction effectively reduces the dimensionality of our genome-wide analysis. We apply our methodology to TCGA data to explore all miRNA-mRNA-SNP combinations from miRNA-gene pairs where the gene was part of a dysregulated miRNA-pathway system, amounting to $\sim 10^6$ models per cancer type (breast, lung, liver, prostate). For each cancer, we report regQTLs which appear to modulate the co-regulatory miRNA-gene relationship in tumors and may therefore contribute to tumorigenesis.

2.1 Analytical approach

We consider all miRNA-gene pairs from dysregulated pathways that exhibited a differential association p < 0.01 in our prior analysis [29]. We systematically probe all unique miRNA-mRNA-SNP trios across all tumor samples in a cancer cohort. For each unique trio, we compute a multiple linear regression to model the expression of a gene as a response as a function of the miRNA expression, the SNP allele (treated as a categorical variable), and the interaction between them. Specifically, for a SNP with genotypes $\{AA, Aa, aa\}$, we fit

$$Y = \beta_0 + \beta_1 X_{\text{miR}} + \beta_2 \mathbb{1}(\text{SNP=Aa}) + \beta_3 \mathbb{1}(\text{SNP=aa}) + \beta_4 \mathbb{1}(\text{SNP=Aa}) X_{\text{miR}} + \beta_5 \mathbb{1}(\text{SNP=aa}) X_{\text{miR}} + \varepsilon,$$
(1)

where Y represents the expression level of the gene of interest, X_{miR} is the expression level of the miRNA, and $\mathbb{1}(\cdot)$ is an indicator function for the SNP genotype. In this model, the coefficient β_1 quantifies the relationship between the miRNA and gene expression for the reference genotype AA; the coefficients β_2 , β_3 quantify how the allele affects overall expression of the gene (i.e., as an eQTL); and the interaction coefficients β_4 , β_5 quantify how the variant alleles at the SNP of interest modulate the miRNA-mRNA relationship. SNPs with strong interaction effects are inferred to be potential regQTLs.

SNPs are treated as categorical variables in our model to capture any dominant, recessive, or additive effects that individual alleles may confer on miRNA-gene interactions. Because any single copy of an allele may create, strengthen, weaken, or abrogate miRNA-gene binding, we seek to capture all possible SNP effects and their cross-comparisons. For instance, an allele that creates strong miRNA-gene binding may only need to be present in one copy to show an effect, such that the salient difference is observed between having no copy of the variant allele and having one or two copies (with no difference between one and two). Alternatively, an allele that abrogates miRNA-gene binding may be seen to have a strong effect for those with homozygous copies, but a much weaker effect for heterozygous individuals. As such, we explore all allelic effects on miRNA-gene binding.

To assess the statistical significance of the interaction effect, we apply ANOVA Type III sums of squares (Yates's weighted squares of means) to compare the full model to that without the interaction terms. A significant F statistic for the interactions suggests that at least one of the variant SNP alleles substantially alters the relationship between the miRNA and the mRNA, on top of any eQTL-like effects. *p*-values for all interactions are then FDR-adjusted [31] for the large number of miRNA-mRNA-SNP trios probed in the dataset. (We choose this Benjamini-Hochberg FDR adjustment because we expect that models with common miRNAs or genes are not strictly independent, and this procedure has been show to provide control of the FDR under dependency [32].) The steps of the method are summarized in Table 1. Figure 1 illustrates the intuition underlying the method.

Table 1: Procedure for assessing genomic variants modulating miRNA-gene interactions

Method for finding regQTLs

- 1. Select dysregulated miRNA-pathway pairs (p < 0.01) following the method from [29] (Figure 1a).
- For each miRNA-pathway pair, find all genes on the pathway and all assayed SNPs on each gene to construct all unique miRNA-mRNA-SNP trios (Figure 1b, top).
- 3. For each trio in Step 2, fit Equation 1 and apply ANOVA to assess statistical significance of the interaction terms (Figure 1b, bottom).
- 4. FDR-adjust the resulting ANOVA *p*-values.
- 5. Report highly significant miRNA-mRNA-SNP trios as potential regQTLs.

2.2 Application to TCGA data

As a proof of concept, we applied this method systematically to tumor samples with combined miRNA expression, gene expression, and SNP genotype data from TCGA.

Data TCGA data were downloaded for BRCA (breast), LIHC (liver), LUSC (lung), and PRAD (prostate) cancers. Tumor samples (TCGA sample type "01") measured across mRNA IlluminaHiSeq_RNASeqV2 (Level 3), miRNA IlluminaHiSeq_miRNASeq (Level 3), and Affymetrix SNP6.0 platforms were used for the analysis, amounting to 699 total tumor samples in breast, 345 in liver, 341 in lung, and 481 in prostate cancer.

Data preprocessing and filtration Briefly, mRNA data were converted to TPM and log2 transformed, and miRNA data were log2 transformed (both with small offsets for the log transformation). In addition, genes and miRNAs were removed from consideration that had very low expression across most samples in the set (defined as genes with median expression $< 10^{-9}$ before TPM conversion and miRNAs having expression ≤ 1 for more than half of the samples in the set before log transformation).

SNPs were filtered out that had a low Birdseed confidence threshold (0.05) for genotype calls in the TCGA pipeline. We used two additional filtration criteria to remove SNPs: a) those having minor allele frequencies (MAF) less than 1% and b) those having genotype frequencies less than 5% across all samples in a cancer dataset. These criteria were imposed to ensure that limited sampling of rare alleles and genotypes would not skew the regression results.

Before applying the regression models, individual samples within a miRNA-mRNA-SNP trio having no appreciable miRNA expression were removed from consideration, since they are not biologically of interest. Additionally, samples having a large Cook's Distance (D > 1) were removed from the regressions and the regressions were recomputed to limit the influence of outliers on the resulting models.

3 Results

We begin by presenting qq-plots of the regQTL p-values across all miRNA-mRNA-SNP trios in TCGA breast, liver, lung, and prostate cancer samples (Figure 2). It can be seen here that several trios in each study achieve extremely small p-values of $p \le 10^{-9}$, indicating regQTLs that achieve genome-wide significance (even using the conservative Bonferroni correction).

It may also be observed that the distribution of regQTL *p*-values exhibit systematic deviations from the expected uniform distribution of *p* values under the null, with many more significant observations than expected by chance for independent tests (as demonstrated by the trend away from the red diagonal lines). Such systematic deviations suggest that the trios are not strictly independent of one another; in classical



Figure 1: Illustration of the procedure to identify regQTLs: SNPs that modify the miRNA-mRNA relationship in dysregulated pathways. The method integrates gene expression, miRNA expression, and SNP data. (a) To aid mechanistic interpretability and reduce the search space, we first identify miRNA–pathway pairs that exhibit significant evidence of differential regulation following [29]. (b) Within each miRNA–identified pathway pair, we construct all miRNA-mRNA-SNP trios for each gene in the pathway (top), and systematically test whether the SNP modifies the expression relationship between the miRNA and the mRNA (bottom). Table 1 details the method.

GWAS, this is often attributable to population substructure driving the results. Here, however, some dependency amongst the tests is expected. Because we consider all known SNPs on each gene, many of the SNPs will be in linkage disequilibrium (LD) owing to their genomic proximity and will be correlated. Variants in LD have been observed in blocks ranging from tens of Kbs to greater 100 Kbp [33], which may be larger than the size of a gene. In addition, because we consider genes within pathways, the expression of the genes may be correlated due to similar co-regulatory mechanisms or cooperate effects within a network. Population substructure may also be a factor in data drawn from diverse genetic populations. However, TCGA heavily samples from European ancestry; we tested for substructure by applying PCA to genotype data, and found that most of the samples comprised a single tight cluster in the first two principal components, as shown in Supplementary Figures S1–S4. Because we expect the tests to exhibit some dependency, we perform multiple hypothesis adjustment using FDR [31,32], rather than using the Bonferroni adjustment, which assumes independent tests and can be excessively conservative otherwise.

3.1 Breast cancer

In breast cancer, $\sim 1.28 \times 10^7$ unique gene-miRNA-SNP trios, drawn from 25,850 miRNA×pathway pairs, were analyzed and shown in Figure 3. Several chromosomes contain clusters of significant observations, as demonstrated by upward spikes within specific genomic regions. These clusters are composed of SNPs at different loci in close proximity with one another whose alleles are in LD. SNPs in LD are influenced by



Figure 2: Quantile-quantile plots of the observed *p*-values for the gene-miRNA-SNP ANOVA interaction tests versus their expected *p*-value distributions (the uniform distribution), tested in each cancer type. There were approximately 1.29×10^7 unique interactions tested in breast, 3.65×10^6 in liver, 8.03×10^6 in lung, and 4.32×10^6 in prostate cancer. A horizontal blue line indicates the threshold for genome–wide significance under the conservative Bonferroni adjustment.

rates of recombination and mutation and reflect evolutionary history. Because of their genomic proximity, SNPs in linkage often lie within the same genes, such that multiple variants in a gene may wield similar biological effects on miRNA regulation, as demonstrated in Figure 3.



Figure 3: Breast cancer manhattan plot. All gene-miRNA-SNP interaction *p*-values mapped to the location of the SNP in the genome. Observations are colored by chromosome. *p*-values are adjusted for the False Discovery Rate.

This is evident when we observe regQTLs, all trios that were flagged as significant after FDR-adjustment $(FDR \leq 0.1)$, of which relatively few achieve significance (3369). Among the flagged regQTLs, some miRNA-gene pairs are represented frequently, with multiple SNPs in the gene appearing to modulate the miRNA-gene relationship. Table 2 lists the miRNA-gene pairs with the largest number of significant regQTLs achieving significance with $FDR \leq 0.1$. (Note that Table 2 is not an exhaustive list but rather displays the highest number of modulating SNPs within miRNA-gene interactions at a given FDR.)

It is notable that in several pairs in Table 2, the miRNA is not predicted to target the gene based off sequence matching from microRNA.org [34]. This may be due to several factors. First, not all miRNA-

Table 2: miRNA-gene pairs containing the most number of gene variants significantly modulating their interactions in breast cancer. "SNPs" indicates the number of associated SNPs on the gene found to significantly modulate (at $p_{FDR} \le 0.1$) the miRNA-gene interaction, out of the total number of known SNPs on the gene. p_{MIN} indicates the most significant interaction *p*-value after FDR-correction. "chr" indicates the chromosome where the SNP is located."target" indicates whether the miRNA is predicted to target the gene based off sequence matching from microRNA.org.

		SN	Ps			
miRNA	gene	associate	d total	p_{MIN}	chr	target
hsa-mir-221	FGF14	14	334	7.57E-04	13	TRUE
hsa-mir-642a	MTOR	14	38	3.97E-03	1	FALSE
hsa-mir-141	FOXO1	13	44	2.16E-02	13	TRUE
hsa-mir-642a	NUP210	13	173	4.93E-02	3	FALSE
hsa-mir-154	ELMO1	10	313	8.67E-04	7	FALSE
hsa-mir-200c	FOXO1	10	44	4.13E-02	13	TRUE
hsa-mir-200c	GALNT10) 10	123	1.04E-02	5	TRUE
hsa-mir-3200	GSPT2	9	15	4.46E-02	Х	FALSE
hsa-mir-125b-2	2 LRRC4C	9	479	4.85E-03	11	FALSE
hsa-mir-141	EDA2R	8	37	6.66E-02	Х	TRUE
hsa-mir-222	FGF14	8	334	3.07E-04	13	TRUE
hsa-mir-141	SFRP2	8	64	1.59E-02	4	FALSE
hsa-mir-190b	TUSC3	8	235	3.07E-04	8	TRUE
hsa-mir-452	TUSC3	8	235	1.50E-02	8	FALSE
hsa-mir-190b	NUP210	7	173	1.77E-02	3	FALSE

gene interactions are known, and some interactions have been observed in experiment that have not been predicted through sequence matching [22]. Because these miRNA-gene pairs are modulated by many gene variants, these may represent novel biological interactions between miRNAs and genes that have yet to be documented and that are sensitive to biological variation. Another possibility is that these miRNAs and genes may not interact directly, but may be indirectly connected through second-order effects—for instance, one can envision a miRNA *target* interacting with the gene listed in the pair in Table 2. This may lead to an apparent association with the miRNA, although it is mediated through another gene.

Examples of significant trios are shown in Figure 4. For instance, in the left panel, samples with the homozygous minor (AA) genotype exhibit a strong negative dependence between hsa-mir-190b and TUSC3, whereas the heterozygous (AC) and homozygous major (CC) genotypes exhibit weaker and no dependencies. One explanation may be that samples having both A alleles confer strong binding between hsa-mir-190b and TUSC3, whereas the introduction of the C allele confers weaker (AC) or no binding (CC) at all. hsa-mir-190b is predicted to target TUSC3 by sequence matching, and both the miRNA and gene are implicated in cancer in the literature. TUSC3 is a tumor suppressor whose loss or decreased expression is associated with the proliferation of several cancer types [35–37] and is markedly under-expressed in breast cancer cells [38]. hsa-mir-190b has recently been found to be the most upregulated miRNA in ER α breast cancers relative to ER α negative breast cancers [39], and is part of the regulatory network that activates p53 [40]. Likewise, in the middle panel, hsa-mir-221 is predicted to target FGF14 and exhibits regulatory differences across genotypes. In this case, the homozygous minor (AA) appears to confer a loss of regulation, whereas the introduction of the G allele in the heterozygous (AG) and homozygous major (GG) genotypes, confers negative regulation and perhaps strong binding. hsa-mir-221/222 has previously been associated with a basal-like phenotype and the epithelial to mesenchymal transition in breast cancer [41]. Although FGF14 in particular is not implicated in cancer, aberrant signaling of other Fibroblast Growth



Figure 4: Examples of breast cancer gene-miRNA-SNP trios with significant regulatory differences across genotypes. All trio interactions $p_{FDR} < 0.005$.

Factors are widely found in the pathogenesis of cancer [42].

In the right panel, the anomalous genotype, homozygous major (GG), is associate with a strong positive dependence between hsa-mir-642a and *MTOR*, in contrast to the other panels. The positive dependence, coupled with the fact that hsa-mir-642a is not predicted to target *MTOR*, may be evidence that our method is flagging second-order effects driven by genomic variation. Furthermore, hsa-mir-642, the miRNA family of hsa-mir-642a, contains many genes that interact with *MTOR*, including many MAP kinases and *TP53* that are implicated in breast cancer in the literature. The examples shown in Figure 4 are illustrative of the types of regulatory interactions affected by genomic variation we observe within breast cancer.

3.2 Liver cancer

A total of 3.65×10^6 gene-miRNA-SNP unique trios, drawn from 7371 miRNA×pathway pairs, were mapped to their loci in the genome in Figure 5 for liver cancer. Although fewer trios achieve significance in comparison to breast cancer (76 regQTLs with $FDR \le 0.1$), we again observe the associated SNPs to be clustered due to linkage. As above, Table 3 presents the miRNA-gene pairs that have the greatest number of regQTLs. The top gene, *POLR3B*, contains 6 SNPs that each modulate its regulation by hsa-mir-182, depending on genotype. We illustrate one such example in Figure 6 (left plot), in which the anomalous genotype (GG) for rs11112983 downregulates expression of *POLR3B* by hsa-mir-182, in comparison to the others. *POLR3B* is subunit B (the second largest) of RNA polymerase III, which is the polymerase that synthesizes transfer and small ribosomal RNAs. Increased RNA polymerase III output is widely implicated in cancer [43]. Recently, a novel truncated version of *POLR3B* called *INMAP* has been observed to repress *AP-1* and *p53* activity and is upregulated in several cancer cell lines [44]. hsa-mir-182 is significantly upregulated in hepatocellular carcinoma and has been found to promote proliferation and invasion by downregulating tumor suppressor *EFNA5* [45] and promote metastasis by downregulating metastasis suppressor 1 [46]. While hsa-mir-182 itself isn't predicted to target *POLR3B*, it is predicted to target other subunits on RNA polymerase III, and therefore may exert second-order regulatory effects with *POLR3B*.

Another example of noteworthy genotype-dependent interactions we detect is shown in Figure 6 (right plot). Not only is *GSTM1* differentially regulated by hsa-mir-99a at rs2071487 depending on genotype, but also *GSTM1* exhibits initial genotype-dependent gene expression differences typical of a strong eQTL. In this case, alleles appear to have the power to determine both expression and modulation of gene regulation. *GSTM1* is part of the GST-superfamily that detoxifies electrophilic compounds by conjugation with glutathione, and is involved in processing carcinogens, drugs, and toxins. *GSMT1* is highly polymorphic, affecting toxicity and drug efficacy across individuals, and in particular, null mutations are associated with an increase in susceptibility to lung, bladder, and colon cancers [47]. hsa-mir-99a inhibits hepatocellular

carcinoma growth [48] and its dysregulation is an early marker of tumor progression [49]. While hsa-mir-99a is not predicted to target *GSTM1*, it is predicted to target *GSTM3* and *GSTM5*, other GST-superfamily μ enzymes.



Figure 5: Liver cancer manhattan plot of regQTL $-log_{10}FDR$ values.

Table 3: miRNA-gene pairs with the greatest number of significant regQTLs (at $p_{FDR} \leq 0.1$) in liver cancer.

		SNI	Ps			
miRNA	gene	associate	d total	p_{MIN}	chr	target
hsa-mir-182	POLR3B	6	34	9.22E-03	12	FALSE
hsa-mir-183	POLR3B	6	34	1.28E-02	12	FALSE
hsa-mir-107	NFYC	3	21	1.28E-02	1	TRUE
hsa-mir-125b-1	STS	3	212	1.18E-02	Х	TRUE
hsa-mir-122	ATP2B2	2	237	8.21E-03	3	TRUE
hsa-mir-655	CACNA1C	2	301	5.19E-02	12	TRUE
hsa-mir-215	DRD1	2	84	5.87E-02	5	FALSE
hsa-mir-139	GLDC	2	51	5.87E-02	9	FALSE
hsa-mir-203	PLCE1	2	118	3.32E-02	10	FALSE
hsa-mir-766	THOP1	2	3	6.74E-02	19	TRUE
hsa-mir-34c	UGT1A6	2	43	5.01E-02	2	FALSE

3.3 Lung cancer

A total of 8.03×10^6 unique gene-miRNA-SNP trios, drawn from from 14433 miRNA×pathway pairs in lung cance were mapped to their loci in the genome in Figure 7. Among the clusters of correlated observations that spike in Figure 7, several miRNA-gene pairs are represented frequently and tabulated in Table 4. *MAOA*, *POLA1*, and *CTNNA2* on Chromosomes X and 2 collectively make up the bulk of the genes containing SNPs modulating their observations in LD with each other.

In Figure 8 (left plot), one of the SNPs (rs5944699) modulating *POLA1* and hsa-mir-337 is shown. All three genotypes exhibit disparate regulation on the gene. Interestingly, the heterozygous genotype (AG) demonstrates a negative regulatory effect rather than the homozygous genotypes. *POLA1* is the catalytic



Figure 6: Examples of liver cancer gene-miRNA-SNP trios with significant regulatory differences across genotypes. All trio interactions $p_{FDR} < 0.005$.

subunit of DNA Polymerase Alpha 1. hsa-mir-337 regulates the proliferation of several cancer types, including pancreatic and gastric cancers.

Yet another example of anomalous regulation we detect is shown in Figure 8 (right plot). Here the CC genotype for rs9372316 exhibits a strong positive correlation between hsa-mir-1247 and *FYN*, in contrast to the other genotypes, which exhibit no appreciable correlation. hsa-mir-1247 is not predicted to target *FYN*, providing additional evidence that we may be detecting secondary effects of allele-specific differences on miRNA regulation of genes. hsa-mir-1247 is predicted to target several genes that interact with *FYN*, including *TNFRSF10B* (tumor necrosis factor receptor) and *CBL* (proto-oncogene), that are implicated in tumorigenic processes. *FYN* itself is a proto-oncogene of the Src family normally associated with T-cell signaling, cell development and growth. *FYN* is upregulated in several cancer types including breast and prostate cancers [50] and is associated with metastatic potential.

We note that in Table 4, *CTNNA2* appears frequently with several miRNAs, often with the same SNPs. Because the anomalous SNPs in *CTNNA2* have relatively low representation among the cohort, it is difficult to attribute confidence to their regulatory effect. That is, genotype frequencies for the homozygous minor alleles (MAF: 28%-41%) may be undersampled for these SNPs (range: 9.9%-16.1%). Another note is that *CTNNA2* has low gene expression in lung tumor samples (< 0.1 TPM for ~ 92\% of the samples). This may subject it to biological fluctuations, due to noise and excluded samples, which may influence results.

3.4 Prostate cancer

A total of 4.3×10^6 unique gene-miRNA-SNP trios, drawn from 8673 miRNA×pathway pairs in prostate cancer were mapped to their loci in the genome in Figure 9. The scale in Figure 9 is lower than the manhattan plots in the other cancer types, with the most significant interaction $p \sim 0.0067$. Nevertheless, we do observe pairs containing many SNPs modulating their interactions in Table 5. In addition, many of these miRNA-gene pairs are predicted to interact biologically based on sequence matching.

A few examples of trios we find in prostate cancer are shown in Figure 10. In the left plot, hsa-mir-30a is predicted to target *FBXW7*, and shows a sharp negative regulatory dependence for the CC genotype, whereas the other genotypes exhibit no appreciable miRNA-gene regulation. hsa-mir-30a and *FBXW7* are



Figure 7: Lung cancer manhattan plot of regQTL $-log_{10}FDR$ values.

among the most frequently flagged pairs we find in prostate cancer. hsa-mir-30a is a tumor suppressor that inhibits EMT genes that is typically down-regulated by oncogenic signals in prostate cancer like *EGF*, particularly in metastasis [51]. *FBXW7*, an F-box protein, mediates ubiquitination and proteasomal degradation of target proteins. Its down-expression, loss, and frequent mutation is shown in multiple cancer types, including ovarian, breast, melanoma, colon, and others. In the right plot, the CC genotype exhibits strong negative regulation between hsa-mir-1307 and *ROBO1*, whereas the other genotypes exhibit weaker dependencies. hsa-mir-1307 is predicted to target *ROBO1*, and promotes proliferation in prostate cancer by targeting *FOXO3A* [52]. *ROBO1* itself is part of the immonoglobulin gene superfamily and is an axon guidance receptor gene previously implicated in dyslexia.

3.5 Tool for interactive exploration of complete results

We have presented only a few examples of gene-miRNA-SNP trios tested in the cancer types shown above. In order to enable researchers to explore other trios, we have produced an open source R Shiny application, called mirApp, that can be used to investigate other trios in the analyzed datasets. The user is asked to choose the cancer type (breast, liver, lung, or prostate) and input a specific miRNA of interest. The Shiny app then produces a miRNA-specific manhattan plot of all significant regQTLs within the cancer type ($p_{FDR} \le 0.1$). This manhattan plot is interactive, such that when the user clicks on an individual regQTL point, the app produces its trio interaction plot, similar to those in Figure 4. This tool can be downloaded freely from https://github.com/gawilk/mirApp.

In addition, code to carry out the analysis (to reproduce these results or apply them to other SNP/miRNA/mRNA datasets) can be obtained from https://github.com/gawilk/miRNA-SNP.

4 Discussion

We have described a novel integrative method that combines genomic and expression data to elucidate the effects that genomic variants exert on miRNA regulation of genes in cancer. This integrative analysis combines miRNA expression, mRNA expression, and genotype data from tumor tissue to find polymorphisms that modulate co-expression patterns between miRNAs and their putative gene targets, which we term regQTLs. This analysis continues our previous work that identified miRNAs and entire pathways

		SNPs				
miRNA	gene	associ	ated total	p_{MIN}	chr	target
hsa-mir-766	MAOA	10	91	1.82E-02	Х	TRUE
hsa-mir-337	POLA1	8	61	6.13E-03	Х	TRUE
hsa-mir-200t	o CTNNA3	7	654	3.44E-02	10	FALSE
hsa-mir-127	CTNNA2	6	732	1.76E-03	2	FALSE
hsa-mir-134	CTNNA2	6	732	1.76E-03	2	FALSE
hsa-mir-154	CTNNA2	6	732	8.51E-03	2	TRUE
hsa-mir-369	CTNNA2	6	732	4.27E-03	2	TRUE
hsa-mir-379	CTNNA2	6	732	6.68E-03	2	FALSE
hsa-mir-409	CTNNA2	6	732	1.76E-03	2	TRUE
hsa-mir-493	CTNNA2	6	732	8.51E-03	2	FALSE
hsa-mir-496	CTNNA2	6	732	8.51E-03	2	FALSE
hsa-mir-758	CTNNA2	6	732	1.65E-02	2	FALSE
hsa-mir-185	ADH4	5	16	4.57E-02	4	TRUE
hsa-mir-382	CTNNA2	5	732	3.44E-02	2	FALSE
hsa-mir-205	EGFR	5	125	3.23E-02	7	TRUE

Table 4: miRNA-gene pairs with the greatest number of significant regQTLs (at $p_{FDR} \le 0.1$) in lung cancer.

whose co-regulation was found to be disrupted in tumors. Here, we hone in on previously identified dysregulated pathways, and determine whether polymorphisms present within pathway genes may contribute to individual gene dysregulation.

This work is in the spirit of other integrative omics analyses to yield insights into gene expression regulatory mechanisms. Its main novelty is to take into account genomic variation and apply it on a genomewide scale. Other integrative analyses of omics platforms have been applied to yield discoveries on gene expression regulation mechanisms. Pipelines such as CrossHub [53] take into account miRNA and TF relationships as well as methylation evidence, through TCGA and ENCODE ChIP-Seq binding evidence, to describe regulation of gene expression. RACER [54] uses regression analysis to predict gene expression as a function of genetic and epigenetic factors including copy number variation, miRNAs, DNA methylation, and TF evidence combined from TCGA and ENCODE to study Acute Myeloid Leukemia. Another study [55] combined similar input variables in a linear fashion to model mRNA expression changes in glioblastoma tumor samples, and was able to identify activities that were predictive of subtypes and survival. These studies have identified some relationships between expression regulators and genes and focused on mostly single cancer types. Jacobsen and colleagues [56] used a statistical approach to model the recurrence of miRNA-mRNA expression in tumor samples across multiple cancer types, induced by changes in DNA copy number and promoter methylation. However, none of these studies have taken into account genomic variation to address their effect on gene regulation.

In contrast, our method incorporates genomic variation to identify regQTLs. Our method is fully data driven, integrating sample specific expression and genomic data to find allele-specific regulatory effects. By applying multiple linear regression models using all three omics features, we can assess which SNPs differentially affect miRNA regulation of genes. The use of linear models and ANOVA allow for relatively easy assessment of statistical interactions. Because we focus on genes within pathways found to be co-regulated with miRNAs which are disrupted in cancer, our approach may help find genomic variants that contribute to tumorigenesis. We emphasize that the application to dysregulated pathways permits the identification of regQTLs with potentially local and system effects, and significantly reduces the search space of mechanisms under consideration in the genome.

We apply this analysis to breast, liver, lung, and prostate cancers, and within each cancer type, test



Figure 8: Examples of lung cancer gene-miRNA-SNP trio with a significant regulatory difference across genotypes. All trio interactions $p_{FDR} < 0.015$.

millions of possible models (genes regulated by miRNAs modulated by SNPs, or "trios"). We find polymorphisms systematically affecting miRNA-gene regulation, with many more statistically significant effects than expected by chance. This supports the notion that cancer contains significant perturbations to the entire genome. Among the flagged trios with high significance, many miRNAs and genes are often implicated in tumorigenic processes in the literature. These include tumor suppressor genes, genes in the the p53 network, genes within signaling pathways, and miRNAs whose aberrant expression or aberrant targeting has been documented in multiple cancer types. In addition, we find several genes each containing many individual variants differentially modulating miRNA regulation. These genes, and the genomic regions surrounding them, may indicate hotspots of tumorigenic interest for future research.

Due to the extensive nature of the study, an R Shiny app has been developed to fully explore all regQTLs and visualize their effects. Users can utilize the app interactively to observe regQTL significance genomewide by cancer type, and plot individual miRNA-gene interactions modulated by them. This utility allows for complete exploration of our integrative analysis of TCGA data.

We note that the our results are somewhat limited by the input data. Currently, TCGA is the largest known resource of cancer omics data, with samples assayed across both expression and genotype data. However, individuals of European ancestry are highly overrepresented. Having comparable datasets in diverse populations would strengthen the results of this study. In addition, our method only considers genes and SNPs which lie on annotated pathways; genes and SNPs that are currently unannotated on biological pathways, and therefore unconsidered in our model, may be of tumorigenic importance. Finally, our search for regQTLs is highly flexible; we do not restrict miRNA-gene relationships to those already corroborated with biophysical evidence, and, in addition, do not restrict genomic variants to those within putative miRNA binding regions. These criteria have been set to allow for novel discoveries, since computational miRNA-gene binding rules have been observed to deviate from experiment. However, we may also identify second-order effects of miRNA regulation modulated by genotype (or possibly spurious relationships) that would require functional experiments to elucidate. Nevertheless, we do find significant relationships in which the genes and miRNAs are implicated in cancers in the literature.

Our model is relatively simple and can be efficiently applied to any combined miRNA/mRNA/SNP dataset of interest to reveal the effects of a single regulatory SNP. We envision that future work could apply



Figure 9: Prostate cancer manhattan plot of regQTL $-log_{10}FDR$ values.

and extend our approach in several ways. For instance, it is conceivable that multiple SNPs in combination will influence miRNA regulation of a gene, and that genomic variation may affect other layers of gene regulation (e.g., but influencing transcription factor binding). Future extensions of this method could include integrating TF binding sites or epigenetic factors in the analysis regQTLs. Given specific regQTLs identified in this study, other avenues could include validating their differential regulation by experimental means, or estimating their strength *in silico*. Perhaps the most exciting future application would be to inform personalized medicine in the context of miRNA therapeutics [57–59]; for instance, the results shown in Figure 4 suggest that targetting *mir-190b* could influence the expression of the tumor suppressor *TUSC3*, but only amongst homozygous AA individuals at regQTL rs13253051.

Finally, we note that our method for identifying regQTLs can be easily applied to other diseases and experimental modalities (such as TFs) to determine the functional impact of specific loci. A genome-wide analysis of functional regulatory effects can help identify polymorphisms and mutations that contribute to disease.

5 Acknowledgements

The results published here are in whole or part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov.

6 Funding

J.S. McDonnell Foundation (to RB); Northwestern University Data Science Initiative (to GW and RB).

6.0.1 Conflict of interest statement.

None declared.

		SN	Ps			
miRNA	gene	associate	d total	p_{MIN}	chr	target
hsa-mir-26a-2	2 CNTN1	14	135	6.68E-03	12	TRUE
hsa-mir-15b	PARK2	6	636	1.96E-02	6	TRUE
hsa-mir-30a	FBXW7	5	33	1.12E-02	4	TRUE
hsa-mir-1266	PDE4D	5	534	7.17E-02	5	TRUE
hsa-mir-143	EFNA5	4	247	2.54E-02	5	FALSE
hsa-mir-200c	FBXW7	4	33	5.99E-02	4	TRUE
hsa-mir-330	NEGR1	4	241	6.93E-02	1	TRUE
hsa-mir-421	WBSCR17	4	336	1.96E-02	7	FALSE
hsa-mir-130b	AKR1C3	3	42	3.86E-02	10	TRUE
hsa-mir-331	CACNA2D4	! 3	53	5.99E-02	12	TRUE
hsa-mir-766	CACNA2D4	4 3	53	6.11E-02	12	TRUE
hsa-mir-330	MASP1	3	55	1.96E-02	3	TRUE
hsa-mir-190	NPR2	3	4	7.38E-02	9	FALSE
hsa-mir-361	NTN4	3	42	2.20E-02	12	TRUE
hsa-mir-151	PRKCE	3	384	5.83E-02	2	TRUE

Table 5: miRNA-gene pairs with the greatest number of significant regQTLs (at $p_{FDR} \leq 0.1$) in prostate cancer.



Figure 10: Examples of prostate cancer gene-miRNA-SNP trios with significant regulatory differences across genotypes. All trio interactions $p_{FDR} < 0.05$.

References

- [1] David P Bartel. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*, 116(2):281–297, 2004.
- [2] Kexin Chen, Fengju Song, George A Calin, Qingyi Wei, Xishan Hao, and Wei Zhang. Polymorphisms in microrna targets: a gold mine for molecular epidemiology. *Carcinogenesis*, 29(7):1306–1311, 2008.
- [3] Stephen T Sherry, M-H Ward, M Kholodov, J Baker, Lon Phan, Elizabeth M Smigielski, and Karl Sirotkin. dbsnp: the ncbi database of genetic variation. *Nucleic Acids Research*, 29(1):308–311, 2001.
- [4] Kelly A Frazer, Dennis G Ballinger, David R Cox, David A Hinds, Laura L Stuve, Richard A Gibbs, John W Belmont, Andrew Boudreau, Paul Hardenbol, Suzanne M Leal, et al. A second generation human haplotype map of over 3.1 million snps. *Nature*, 449(7164):851–861, 2007.
- [5] David W Salzman and Joanne B Weidhaas. Snping cancer in the bud: microrna and microrna-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. *Pharmacology & Therapeutics*, 137(1):55–63, 2013.
- [6] Adrianna Moszyńska, Magdalena Gebert, James F Collawn, and Rafał Bartoszewski. Snps in microrna target sites and their potential role in human disease. *Open Biology*, 7(4):170019, 2017.
- [7] Praveen Sethupathy and Francis S Collins. Microrna target site polymorphisms and human disease. *Trends in Genetics*, 24(10):489–497, 2008.
- [8] Milena S Nicoloso, Hao Sun, Riccardo Spizzo, Hyunsoo Kim, Priyankara Wickramasinghe, Masayoshi Shimizu, Sylwia E Wojcik, Jana Ferdin, Tanja Kunej, Lianchun Xiao, et al. Singlenucleotide polymorphisms inside microrna target sites influence tumor susceptibility. *Cancer Research*, 70(7):2789–2798, 2010.
- [9] Sofia Khan, Dario Greco, Kyriaki Michailidou, Roger L Milne, Taru A Muranen, Tuomas Heikkinen, Kirsimari Aaltonen, Joe Dennis, Manjeet K Bolla, Jianjun Liu, et al. Microrna related polymorphisms and breast cancer risk. *PLoS One*, 9(11):e109973, 2014.
- [10] Hushan Yang, Colin P Dinney, Yuanqing Ye, Yong Zhu, H Barton Grossman, and Xifeng Wu. Evaluation of genetic variants in microrna-related genes and risk of bladder cancer. *Cancer Research*, 68(7):2530–2537, 2008.
- [11] Alessio Naccarati, Barbara Pardini, Landi Stefano, Debora Landi, Jana Slyskova, Jan Novotny, Miroslav Levy, Veronika Polakova, Ludmila Lipska, and Pavel Vodicka. Polymorphisms in mirnabinding sites of nucleotide excision repair genes and colorectal cancer risk. *Carcinogenesis*, 33(7):1346–1351, 2012.
- [12] Lila E Mullany, Roger K Wolff, Jennifer S Herrick, Matthew F Buas, and Martha L Slattery. Snp regulation of microrna expression and subsequent colon cancer risk. *PLoS One*, 10(12):e0143894, 2015.
- [13] Anindya Bhattacharya, Jesse D Ziebarth, and Yan Cui. Polymirts database 3.0: linking polymorphisms in micrornas and their target sites with human diseases and biological pathways. *Nucleic Acids Research*, 42(D1):D86–D91, 2013.

- [14] Samuel Hiard, Carole Charlier, Wouter Coppieters, Michel Georges, and Denis Baurain. Patrocles: a database of polymorphic mirna-mediated gene regulation in vertebrates. *Nucleic Acids Research*, 38(suppl_1):D640–D651, 2009.
- [15] Manoj Hariharan, Vinod Scaria, and Samir K Brahmachari. dbsmr: a novel resource of genome-wide snps affecting microrna mediated regulation. *BMC Bioinformatics*, 10(1):108, 2009.
- [16] Sunil Kumar, Giovanna Ambrosini, and Philipp Bucher. Snp2tfbs-a database of regulatory snps affecting predicted transcription factor binding site affinity. *Nucleic Acids Research*, 45(D1):D139–D144, 2017.
- [17] Kris Richardson, Chao-Qiang Lai, Laurence D Parnell, Yu-Chi Lee, and Jose M Ordovas. A genomewide survey for SNPs altering microrna seed sites identifies functional candidates in gwas. BMC Genomics, 12(1):504, 2011.
- [18] Owen M Wilkins, Alexander J Titus, Jiang Gui, Melissa Eliot, Rondi A Butler, Erich M Sturgis, Guojun Li, Karl T Kelsey, and Brock C Christensen. Genome-scale identification of microRNA-related SNPs associated with risk of head and neck squamous cell carcinoma. *Carcinogenesis*, 2017.
- [19] Bríd M Ryan, Ana I Robles, and Curtis C Harris. Genetic variation in microrna networks: the implications for cancer research. *Nature Reviews Cancer*, 10(6):389–402, 2010.
- [20] Maxim Barenboim, Brad J Zoltick, Yongjian Guo, and Daniel R Weinberger. MicroSNiPer: a web tool for prediction of snp effects on putative microRNA targets. *Human Mutation*, 31(11):1223–1232, 2010.
- [21] Mehmet Deveci, Ümit V Çatalyürek, and Amanda Ewart Toland. mrSNP: Software to detect SNP effects on microRNA binding. *BMC Bioinformatics*, 15(1):73, 2014.
- [22] Sung Wook Chi, Gregory J Hannon, and Robert B Darnell. An alternative mode of microRNA target recognition. *Nature Structural & Molecular Biology*, 19(3):321–327, 2012.
- [23] Qiyuan Li, Ji-Heui Seo, Barbara Stranger, Aaron McKenna, Itsik Peer, Thomas LaFramboise, Myles Brown, Svitlana Tyekucheva, and Matthew L Freedman. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. *Cell*, 152(3):633–641, 2013.
- [24] Qing-Rong Chen, Ying Hu, Chunhua Yan, Kenneth Buetow, and Daoud Meerzaman. Systematic genetic analysis identifies Cis-eQTL target genes associated with glioblastoma patient survival. *PLoS One*, 9(8):e105393, 2014.
- [25] Max Shpak, Amelia Weber Hall, Marcus M Goldberg, Dakota Z Derryberry, Yunyun Ni, Vishwanath R Iyer, and Matthew C Cowperthwaite. An eQTL analysis of the human glioblastoma multiforme genome. *Genomics*, 103(4):252–263, 2014.
- [26] Zhihong Zhu, Futao Zhang, Han Hu, Andrew Bakshi, Matthew R Robinson, Joseph E Powell, Grant W Montgomery, Michael E Goddard, Naomi R Wray, Peter M Visscher, et al. Integration of summary data from gwas and eqtl studies predicts complex trait gene targets. *Nature Genetics*, 48(5):481–487, 2016.
- [27] Vessela N Kristensen, Ole Christian Lingjærde, Hege G Russnes, Hans Kristian M Vollan, Arnoldo Frigessi, and Anne-Lise Børresen-Dale. Principles and methods of integrative genomic analyses in cancer. *Nature Reviews Cancer*, 14(5):299–313, 2014.

- [28] Yan V. Sun and Yi-Juan Hu. Chapter three integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. volume 93 of *Advances in Genetics*, pages 147 – 190. Academic Press, 2016.
- [29] Gary Wilk and Rosemary Braun. Integrative analysis reveals disrupted pathways regulated by micrornas in cancer. *Nucleic Acids Research*, 46(3):1089–1101, 2018.
- [30] Joshua B Tenenbaum, Vin De Silva, and John C Langford. A global geometric framework for nonlinear dimensionality reduction. *Science*, 290(5500):2319–2323, 2000.
- [31] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, pages 289–300, 1995.
- [32] Yoav Benjamini and Daniel Yekutieli. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics, pages 1165–1188, 2001.
- [33] David E Reich, Michele Cargill, Stacey Bolk, James Ireland, Pardis C Sabeti, Daniel J Richter, Thomas Lavery, Rose Kouyoumjian, Shelli F Farhadian, Ryk Ward, et al. Linkage disequilibrium in the human genome. *Nature*, 411(6834):199–204, 2001.
- [34] Doron Betel, Manda Wilson, Aaron Gabow, Debora S Marks, and Chris Sander. The microrna.org resource: targets and expression. *Nucleic Acids Research*, 36(Suppl 1):D149–D153, 2008.
- [35] Petr Vaňhara, Peter Horak, Dietmar Pils, Mariam Anees, Michaela Petz, Wolfgang Gregor, Robert Zeillinger, and Michael Krainer. Loss of the oligosaccharyl transferase subunit tusc3 promotes proliferation and migration of ovarian cancer cells. *International Journal of Oncology*, 42(4):1383–1389, 2013.
- [36] Peter Horak, Erwin Tomasich, Petr Vaňhara, Kateřina Kratochvílová, Mariam Anees, Maximilian Marhold, Christof E Lemberger, Marion Gerschpacher, Reinhard Horvat, Maria Sibilia, et al. Tusc3 loss alters the er stress response and accelerates prostate cancer growth in vivo. *Scientific Reports*, 4, 2014.
- [37] Xiaoqiang Fan, Xiu Zhang, Jie Shen, Haibin Zhao, Xuetao Yu, Yong?an Chen, Zhuonan Zhuang, Xiaolong Deng, Hua Feng, Yunfei Wang, et al. Decreased tusc3 promotes pancreatic cancer proliferation, invasion and metastasis. *PLoS One*, 11(2):e0149028, 2016.
- [38] Indira Poola, Jessy Abraham, Josephine J Marshalleck, Qingqi Yue, Sidney W Fu, Lokesh Viswanath, Nikhil Sharma, Russel Hill, Robert L DeWitty, and George Bonney. Molecular constitution of breast but not other reproductive tissues is rich in growth promoting molecules: a possible link to highest incidence of tumor growths. *FEBS Letters*, 583(18):3069–3075, 2009.
- [39] Geraldine Cizeron-Clairac, François Lallemand, Sophie Vacher, Rosette Lidereau, Ivan Bieche, and Celine Callens. MiR-190b, the highest up-regulated mirna in $er\alpha$ -positive compared to $er\alpha$ -negative breast tumors, a new biomarker in breast cancers? *BMC Cancer*, 15(1):1, 2015.
- [40] Y Yu, D Zhang, H Huang, J Li, M Zhang, Y Wan, J Gao, and C Huang. Nf-κb1 p50 promotes p53 protein translation through mir-190 downregulation of phlpp1. *Oncogene*, 33(8):996–1005, 2014.
- [41] Susanna Stinson, Mark R Lackner, Alex T Adai, Nancy Yu, Hyo-Jin Kim, Carol O?Brien, Jill Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, et al. Trps1 targeting by mir-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. *Science Signaling*, 4(177):ra41–ra41, 2011.

- [42] Nicholas Turner and Richard Grose. Fibroblast growth factor signalling: from development to cancer. *Nature Reviews Cancer*, 10(2):116–129, 2010.
- [43] Lynne Marshall and Robert J White. Non-coding rna production by rna polymerase iii is implicated in cancer. *Nature Reviews Cancer*, 8(12):911–914, 2008.
- [44] Zhou Yunlei, Chen Zhe, Lei Yan, Wang Pengcheng, Zheng Yanbo, Sun Le, and Liang Qianjin. Inmap, a novel truncated version of polr3b, represses ap-1 and p53 transcriptional activity. *Molecular and Cellular Biochemistry*, 374(1-2):81–89, 2013.
- [45] Tong-Hong Wang, Chau-Ting Yeh, Jar-Yi Ho, Kwai-Fong Ng, and Tse-Ching Chen. Oncomir mir-96 and mir-182 promote cell proliferation and invasion through targeting ephrina5 in hepatocellular carcinoma. *Molecular Carcinogenesis*, 55(4):366–375, 2016.
- [46] Jian Wang, Jingwu Li, Junling Shen, Chen Wang, Lili Yang, and Xinwei Zhang. Microrna-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer, 12(1):1, 2012.
- [47] S Zhong, AH Wyllie, D Barnes, CR Wolf, and NK Spurr. Relationship between the gstm1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. *Carcinogenesis*, 14(9):1821– 1824, 1993.
- [48] Dong Li, Xingguang Liu, Li Lin, Jin Hou, Nan Li, Chunmei Wang, Pin Wang, Qian Zhang, Peng Zhang, Weiping Zhou, et al. Microrna-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. *Journal of Biological Chemistry*, 286(42):36677–36685, 2011.
- [49] A Petrelli, A Perra, K Schernhuber, M Cargnelutti, A Salvi, C Migliore, E Ghiso, A Benetti, S Barlati, GM Ledda-Columbano, et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. *Oncogene*, 31(42):4517–4526, 2012.
- [50] Edwin M Posadas, Hikmat Al-Ahmadie, Victoria L Robinson, Ramasamy Jagadeeswaran, Kristen Otto, Kristen E Kasza, Maria Tretiakov, Javed Siddiqui, Kenneth J Pienta, Walter M Stadler, et al. Fyn is overexpressed in human prostate cancer. *BJU International*, 103(2):171–177, 2009.
- [51] Chiao-Jung Kao, Anthony Martiniez, Xu-Bao Shi, Joy Yang, Christopher P Evans, Albert Dobi, Ralph W deVere White, and Hsing-Jien Kung. mir-30 as a tumor suppressor connects egf/src signal to erg and emt. *Oncogene*, 33(19):2495–2503, 2014.
- [52] Xiaodi Qiu and Ying Dou. mir-1307 promotes the proliferation of prostate cancer by targeting foxo3a. *Biomedicine & Pharmacotherapy*, 88:430–435, 2017.
- [53] George S Krasnov, Alexey A Dmitriev, Nataliya V Melnikova, Andrew R Zaretsky, Tatiana V Nasedkina, Alexander S Zasedatelev, Vera N Senchenko, and Anna V Kudryavtseva. CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms. *Nucleic Acids Research*, page gkv1478, 2016.
- [54] Yue Li, Minggao Liang, and Zhaolei Zhang. Regression analysis of combined gene expression regulation in acute myeloid leukemia. *PLoS Computational Biology*, 10(10):e1003908, 2014.

- [55] Manu Setty, Karim Helmy, Aly A Khan, Joachim Silber, Aaron Arvey, Frank Neezen, Phaedra Agius, Jason T Huse, Eric C Holland, and Christina S Leslie. Inferring transcriptional and microrna-mediated regulatory programs in glioblastoma. *Molecular Systems Biology*, 8(1):605, 2012.
- [56] Anders Jacobsen, Joachim Silber, Girish Harinath, Jason T Huse, Nikolaus Schultz, and Chris Sander. Analysis of microrna-target interactions across diverse cancer types. *Nature Structural & Molecular Biology*, 20(11):1325–1332, 2013.
- [57] Vivien Wang and Wei Wu. Microrna-based therapeutics for cancer. *BioDrugs*, 23(1):15–23, 2009.
- [58] Andrea L Kasinski, Kevin Kelnar, Carlos Stahlhut, Esteban Orellana, Jane Zhao, Eliot Shimer, Sarah Dysart, Xiaowei Chen, Andreas G Bader, and Frank J Slack. A combinatorial microrna therapeutics approach to suppressing non-small cell lung cancer. *Oncogene*, 34(27):3547, 2015.
- [59] Maitri Y Shah, Alessandra Ferrajoli, Anil K Sood, Gabriel Lopez-Berestein, and George A Calin. microrna therapeutics in cancer—an emerging concept. *EBioMedicine*, 12:34–42, 2016.

7 Supplementary Information

7.1 Source code

Source code for this analysis is available from https://github.com/gawilk/miRNA-SNP

7.2 SNP PCA plots

We applied PCA to SNP genotype data to test for population substructure. Although TCGA heavily samples from European ancestry, there are other ancestry groups represented. Nevertheless, most of the samples heavily cluster within the first two principal components, even in cancer types which have large sample sizes of other or unknown ancestry, suggesting little population substructure in the cohort. PCA was applied using the snpStats [1] package in R.



Figure 11: PCA plot of Breast SNP genotype data. The entire cohort (left plot) and the main cluster zoomed in (right plot) for the first two principal components. Sample groups appear to cluster together and exhibit little population substructure.



Figure 12: PCA plot of Liver SNP genotype data.



Figure 13: PCA plot of Lung SNP genotype data.



Figure 14: PCA plot of Prostate SNP genotype data.

References

[1] David Clayton (2015) snpStats: SnpMatrix and XSnpMatrix classes and methods R package version 1.24.0.